Therapy with cladribine is efficient and safe in patients previously treated with natalizumab

BACKGROUND: The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have beco...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhn, Nora, Skripuletz, Thomas, Sühs, Kurt-Wolfram, Menck, Sylvia, Voß, Elke, Stangel, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887806/
https://www.ncbi.nlm.nih.gov/pubmed/31832100
http://dx.doi.org/10.1177/1756286419887596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887806/
https://www.ncbi.nlm.nih.gov/pubmed/31832100
http://dx.doi.org/10.1177/1756286419887596

Ejemplares similares